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Paraproteinemia potentially causes peripheral neuropathy via an unknown underlying pathogenetic mechanism. 
We report a case of pathologically proven amyloid neuropathy with AL amyloidosis with an IgA kappa light chain, 
which was initially diagnosed as neuropathy associated with monoclonal gammopathy of undetermined significance. 
This case indicates that in cases of neuropathy with paraproteinemia, the other potential causes should be 
excluded by appropriate means, especially pathological evaluations.
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Monoclonal gammopathy is a condition in which 
aberrant monoclonal immunoglobulin is produced from 
clonally expanded B lymphocyte and is present in 
excessive amounts in the blood, and occurs in about 1% 
of the general population. Identifying monoclonal gammo-
pathy requires the physician to work-up the possible 
underlying lymphoproliferative disorders, such as multiple 
myeloma, osteosclerotic myeloma, and Waldenström’s 
macroglobulinemia.
1 It has also been claimed to be a 
cause of otherwise idiopathic polyneuropathy, which is 
present in 10% of neuropathic patients without any 
systemic disorder known to cause neuropathy,
2  such as 
diabetes mellitus, alcoholism, and connective-tissue dis-
orders. Anti-myelin-associated glycoprotein (MAG) anti-
body, which is identified in about a half of neuropathic 
patients with IgM paraproteinemia,
3 has been considered 
to have a major pathogenetic role in neuropathies. 
However, in most instances there are no nerve-specific 
antibodies identifiable in neuropathy with monoclonal 
gammopathy, and hence the causative role of parapro-
teinemia is not clear, and its nosological entity, so-called 
paraproteinemic neuropathy, is dubious. Furthermore, 
although neuropathy is associated exceedingly more 
frequently with IgM than with IgG or IgA monoclonal 
gammopathy, IgG/IgA paraproteinemia-associated neuro-
pathies also have been reported infrequently, and their 
underlying cause has not been determined.
4,5 Here we 
present a case of neuropathy associated with IgA 
monoclonal gammopathy, and discuss some diagnostic 
considerations related to identifying the underlying 
cause.
CASE REPORT
A 69-year-old man visited a hospital with complaints 
of orthostatic intolerance, burning ache, and weakness in 
distal extremities that had been present for more than 5 Jhang YS, et al. Polyneuropathy Associated with IgA Paraproteinemia and Amyloidosis
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Figure 1. Deposition of amorphous materials in the endoneurium was indicated in sections stained with H&E (A) that exhibited 
birefringence under polarized-light microscopy with Congo red staining (B, arrows).
months. He had previously been evaluated at another 
hospital for the same complaints, where he had been 
diagnosed as having ‘sensorimotor polyneuropathy 
associated with IgA kappa (κ) light-chain monoclonal 
gammopathy of undetermined significance’ (MGUS) 
based on an electrophysiological investigation, protein 
electrophoresis (PEP), immunoelectrophoresis (IEP), and 
the normal appearance of a bone marrow biopsy 
specimen, but the pathology of his peripheral nerves 
had not been investigated.
He had taken oral prednisolone at 1 mg/kg/day for 
more than 3 months, but his symptoms had gradually 
worsened. On admission, he was alert and cooperative. 
A physical examination revealed symmetric distal muscle 
atrophy and weakness, but tendon reflexes were excep-
tionally well preserved even at the ankle. In the same 
distal areas of limbs he complained of numbness, 
paresthesia, allodynia, and anhidrosis. His supine blood 
pressure of 130/80 mmHg dropped to 106/80 mmHg at 
3 minutes after standing, during which he complained of 
lightheadedness. Nerve conduction and electromyo-
graphy investigations revealed diffuse axonal sensori-
motor polyneuropathy without apparent electrophysio-
logic indication of demyelination or myopathy. The 
sympathetic skin response and the Valsalva ratio were 
compatible with dysfunction of the autonomic nervous 
system. PEP and IEP reaffirmed the presence of IgA κ 
light-chain monoclonal gammopathy with a serum IgA 
concentration of 509 mg/dl as determined by nephelo-
metry (normal range: 70~400 mg/dl). Radiological investi-
gations revealed neither lytic nor sclerotic bone lesions, 
and blood data including complete blood count, serum 
creatinine, and blood urea nitrogen were normal.
Considering the clinical picture of autonomic and 
sensory dysfunction and the presence of a rare asso-
ciation of neuropathy with IgA MGUS, we biopsied the 
right sural nerve due to suspected other causes of 
neuropathy including amyloidosis. The deposition of 
amorphous materials in the endoneurium was indicated 
in sections stained with H&E (Fig. 1-A) that exhibited 
birefringence under polarized-light microscopy with 
Congo red staining (Fig. 1-B). Transverse cryostat 
sections were examined by direct immunofluorescence 
microscopy using rabbit antisera monospecific to human 
IgG, IgM, and IgA κ and λ light chains, C3, fibrinogen, 
and C1d, which revealed no immunofluorescence re-
actions. Ultrastructural examination disclosed moderately 
decreased myelinated and unmyelinated fibers with 
haphazardly arranged nonbranching amyloid fibrils in 
the endoneurium (Fig. 2). Thus the patient was diag-
nosed as having amyloid neuropathy complicating pri-
mary immunoglobulin-light-chain-related (AL) amy-
loidosis, rather than neuropathy associated with IgA 
MGUS. A comprehensive work-up revealed that no 
organ outside the peripheral nervous system was in-
volved in the amyloidosis.Journal of Clinical Neurology: Vol. 3, No. 2, 2007
- 118 -
Figure 2. Ultrastructural examination showed that both myeli-
nated and unmyelinated fibers had nonbranching amyloid 
fibrils in a haphazard arrangement in the endoneurium.
Administration of corticosteroid and melphalan for 
more than 6 months produced no objective clinical or 
electrophysiological improvement. His neuropathic pain 
was only partially relieved by a transdermal fentanyl 
patch, and no evidence of other organ involvement was 
detected.
DISCUSSION
About 60% of cases with monoclonal gammopathy 
are classified as MGUS after excluding various lympho-
proliferative disorders. MGUS is defined by the presence 
of serum monoclonal protein at less than 30 g/L, fewer 
than 10% of plasma cells in bone marrow, the absence 
of lytic bone lesions, and no related anemia, hyper-
calcemia, or renal insufficiency.
1 In our patient, evalu-
ation of paraproteinemia via the recommended modalities 
produced a diagnosis of MGUS. However, when mono-
clonal gammopathy is associated with sensorimotor 
polyneuropathy (particularly if autonomic involvement is 
present), nephritic syndrome, congestive heart failure, or 
idiopathic malabsorption syndrome, the possibility of AL 
amyloidosis must be considered.
Nerve tissue can be damaged by paraproteins directly 
through deposition of the antibodies specific for a 
myelin or axonal component, as evident in neuropathic 
cases with anti-MAG antibodies. Moreover, amyloid 
deposition or local ischemia due to serum hyperviscosity 
in cryoglobulinemia can also result in nerve damage.
6 
The anti-MAG antibody is identified in more than 50% 
of cases with IgM monoclonal gammopathy, whereas it 
is rare for a specific neural autoantibody to be present 
in IgG or IgA monoclonal gammopathy. Various clinical 
features of peripheral neuropathy associated with IgG/ 
IgA paraproteinemia contrast with the relatively homo-
genous clinical features of peripheral neuropathy with 
IgM neuropathy, which is described under the various 
terms ‘IgM-MGUS neuropathy’, ‘anti-MAG neuropathy’, 
and ‘distal acquired demyelinating symmetric neuro-
pathy’. These observations suggest nonimmunological 
pathomechanisms of neuropathy, which is supported by 
reports of only a few cases with histologically proven 
immunoglobulin deposition in the setting of IgG or IgA 
paraproteinemia.
7–10
The presence of paraproteinemia increases the pro-
bability of neuropathy tenfold, with it being present 
in about 10% of patients with paraproteinemia. This 
means that about 90% of paraproteinemic patients do not 
exhibit peripheral neuropathy. Therefore, the mere 
presence of paraproteinemia itself serves as a strong risk 
factor for peripheral neuropathy, but cannot be consi-
dered as indicative of peripheral neuropathy, especially 
in the case of IgG or IgA paraproteinemia, for which the 
risk for neuropathy is lower than that of IgM parapro-
teinemia. Some previous investigations of neuropathy 
associated with IgG/IgA monoclonal gammopathy did 
not perform the histological evaluations required for a 
definitive diagnosis.
4,5 
Bone marrow biopsy, skeletal investigation, peripheral 
blood smear, and other blood and urine assays are 
sufficient for diagnosing MGUS, but paraproteinemia 
associated with neuropathy is more problematic. Even 
after the exclusion of lymphoproliferative disorder, 
excluding the rare disorder amyloid neuropathy by 
pathological evaluation in the setting of paraproteinemic 
neuropathy is preferable not only for diagnosis accuracy 
but also for selecting the appropriate management. Our 
patient provided no clinical or laboratory evidence of 
other organ involvement, and was a good example for 
illustrating the importance of histological evaluation.Jhang YS, et al. Polyneuropathy Associated with IgA Paraproteinemia and Amyloidosis
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